MAGEA2 and prostate carcinoma: Taken together, this is the first report on the use of MAGE-A2-LP to design a DC cancer vaccine, revealing that pulsed DCs generated from prostatic cancer monocytes were capable of inducing immune responses through T cell proliferation and cytotoxic activation.